Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model
- 1 February 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (2) , 805-807
- https://doi.org/10.1128/aac.01009-08
Abstract
The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (10 8 CFU/ml). A high bacterial load of >10 5 CFU/ml persisted for all strains with doses up to 5 g every 12 h against high inoculum amounts. No change in the vancomycin MIC was detected in any isolate at a moderate inoculum amount (10 6 CFU/ml), and bactericidal activity occurred only against the non-hVISA isolate (time to 99% kill, 7.5 h; P = 0.001).Keywords
This publication has 8 references indexed in Scilit:
- Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 105and 107CFU Injected into Opposite Thighs of Neutropenic MiceAntimicrobial Agents and Chemotherapy, 2013
- Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia in a Tertiary Care CenterJournal of Clinical Microbiology, 2007
- A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to GlycopeptidesJournal of Clinical Microbiology, 2007
- Impact of High-InoculumStaphylococcus aureuson the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2004
- Treatment Outcomes for Serious Infections Caused by Methicillin‐ResistantStaphylococcus aureuswith Reduced Vancomycin SusceptibilityClinical Infectious Diseases, 2004
- Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin‐IntermediateStaphylococcus aureusClinical Infectious Diseases, 2004
- Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract InfectionsClinical Pharmacokinetics, 2004
- Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinThe Lancet, 1997